Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2024 | Story André Damons | Photo Suplied
Dr Claudia Ntsapi
Dr Matlakala C Ntsapi is a Senior Lecturer and researcher in the Department of Basic Medical Sciences at the UFS.

A researcher from the University of the Free State (UFS) is investigating the potential benefits of medicinal plants as supplementary treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

The work of Dr Matlakala Claudia Ntsapi, Senior Lecturer in the Department of Basic Medical Sciences at the UFS, focuses on preserving human brain health to delay or prevent age-related conditions.

According to her, while the primary focus is on age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, the bioactive compounds in these medicinal plants may also have therapeutic potential for other neurological disorders, various types of cancers and Type 2 Diabetes. The broad protective effects of these plant-based bioactive compounds could make them relevant in the potential treatment of other diseases involving oxidative stress and inflammation.

She is involved in several multidisciplinary projects, collaborating with research experts from Denmark, the UK, and various national institutions such as the Central University of Technology (CUT), North West University (NWU), and the Stellenbosch University (SUN), as well as colleagues from the UFS. 

The potential of medicinal plants

“In collaboration with experts from our institution, the CUT and SU, who have strong backgrounds in pharmacology and ethnobotany, we are focusing on underexplored medicinal plants and nutraceuticals. These plants contain bioactive compounds with potential neuroprotective properties, which are believed to provide extra health benefits beyond basic nutritional value,” says Dr Ntsapi.

“We hope that these medicinal plants have the potential to preserve cognitive function and slow the progression of neurodegenerative diseases like Alzheimer’s. Specifically, we aim to identify novel therapeutic targets and discover new avenues for intervention that can improve the quality of life for individuals affected by age-related brain conditions,” she says.

Identifying therapeutic targets and discovering new interventions

The bioactive compounds found in selective medicinal plants and nutraceuticals, explains Dr Ntsapi, serve as a promising source of ‘natural’ therapeutics that may be safer and have fewer side effects compared to conventional synthetic drugs. Additionally, the untapped potential of these compounds for neuroprotection and the preservation of brain health could provide innovative therapeutic solutions. These compounds may be used as complementary therapies to existing drugs, which often have limited efficacy on their own, thereby enhancing overall treatment outcomes for neurodegenerative diseases.

“By utilising cutting-edge techniques, such the innovative CelVivo ClinoStar 2 System, we strive to gain insights into the safety and efficacy of underexplored medicinal plants in preserving cognitive function and slowing disease progression.

“By exploring the untapped potential of bioactive compounds found in medicinal plants and nutraceuticals, our research group aims to contribute to the identification of novel therapeutic targets and the discovery of new avenues for intervention to improve the quality of life for individuals affected by age-related brain conditions,” says Dr Ntsapi.

The researchers, in collaboration with others in the UFS School of Clinical Medicine, will develop 3D cell-based models of the human cortex and hippocampus by utilising the CelVivo ClinoStar 2 System. This cutting-edge technology, housed in an easy-to-use CO² incubator, mimics ‘animal model-like’ conditions with low sheer stress, allowing scientists to generate cell-based models that closely resemble real-world conditions.

Dr Ntsapi explains that they will specifically focus on the technologies’ applications in studying age-related neurodegenerative disorders, such as Alzheimer’s disease. The potential impact of this research is immense, as it could contribute to the development of novel therapeutic strategies for combating the debilitating progression of neurodegenerative diseases, and ultimately improving the quality of life for affected individuals.

Hope for the research

“Our hope for this research is to significantly advance our understanding of neurodegenerative disease progression and to develop novel therapeutic strategies that can effectively combat these debilitating conditions. Ultimately, we aim to improve the quality of life for individuals affected by neurodegenerative diseases by preserving cognitive function and slowing disease progression.

“This research will contribute to the knowledge pool in this field, with the potential to lead to groundbreaking discoveries in the treatment of Alzheimer’s disease and other related disorders, potentially contributing to the policy guidelines on how these conditions are managed and treated,” she says.

The international partners from Denmark and the UK have made their expertise and facilities available to postgraduate students from the UFS, some of whom they are co-supervising.

Dr Ntsapi, who is passionate about exploring innovative solutions to address the gradual decline in normal brain function associated with aging, was this year one the university’s nominations for the prestigious 2023/2024 NSTF-South32 Awards, popularly known as the “Science Oscars” of South Africa. 

News Archive

Conference: Expanded ARV treatment
2005-03-02

VENUE: University of the Free State, Bloemfontein, South Africa
DATE: 30 March 2005 - 1 April 2005

  • ARV Programme as on 24Feb Download Word document
     
  • Programme Special events Download Word document


    Official web site www.fshealth.gov.za/subsites/arvc

     


    Rationale for the Conference
    At the time of the planned Conference, much ground would have been covered, both in the Free State and in South Africa, in respect of the expanded public sector ARV treatment programme in respect of research, experiences in practice, training of staff, treatment of patients, lessons learned, successes and failures, etc. The time would then be quite opportune to share these in a systematic manner with other provinces and countries, as well as with the large variety of stakeholders and role players in the ARV and related domains, be they academics and researchers, policy makers and service/facility managers, the variety of caregivers, and the community organisations and affected patients.

The Conference and current research
The proposed Conference is, firstly, directly linked to the current research on the public sector roll-out of ARV treatment in the Free State conducted by several research institutions (e.g. CIET, CHSR&D, UCT Lung Institute). Secondly, the Conference could and would serve as a forum for other research groups in the country and further a field to report and share knowledge and experiences on ARV treatment and related initiatives. Lastly, the Conference will stage a golden opportunity for researchers and scientists, on the one hand, and policy makers, managers, and caregivers (as knowledge users), on the other hand, to engage in cross-disciplinary discourse on this mutual and topical theme.

Theme of Conference
Expanded ARV treatment in the Free State: sharing experiences

Focus
The focus is primarily on public sector ARV treatment in the Free State, but also initiatives/activities/perspectives of relevance to the Free State elsewhere in the country at large and further a field, as well as relevant ARV initiatives in the public, private, NGO and FBO sectors. Bear in mind, however, that ARV treatment is but part of a much more comprehensive approach to HIV and AIDS. The Conference will, therefore, not narrowly focus on the ARV treatment programme only. The broader context, other relevant dimensions, and a comprehensive approach to the challenges of HIV, AIDS and TB are of equal importance.

The purpose of the Conference
Enhance meaningful exchange, mutual understanding and collaboration among researchers, scientists, policy makers, managers and practitioners in the field of ARV treatment and related fields.

Share experiences in the various spheres of ARV treatment and related spheres (policy, management, practice, research, training, public-private-civil society sectors).

Record, reflect and report on the establishment of the ARV treatment programme in the Free State, and in within the context of the comprehensive HIV/AIDS programme.

Disseminate important research results on ARV treatment and related themes to health policy makers, managers, practitioners, communities and to the research community.

Stimulate discourse among various disciplines and various stakeholders/role players involved in ARV treatment and related programmes.

Sensitise and acquaint researchers to the requirements of policy makers, managers and practitioners in respect of ARV treatment and related fields.

Facilitate the implementation of research results in ARV treatment policy, programmes and practice.

Dissemination of Conference-related information
Information generated during the Conference could feed into policy, management and practice of ARV treatment, the training accompanying such programme, and the existing body of knowledge. After the Conference the information will be disseminated via the Internet and by scientific and popular publications.

Date and duration
Set for 30 & 31 March & 1 April 2005; to commence at 09:00 on the first day (30 March) and to end at 16:30 (1 April) the third day.

Format and scope of Conference
Alternating plenary, parallel sessions and debates focused on topical issues and interest groups. The Conference will strive to be maximally interactive and participative.

Themes and topics to cover:

  • Policy, management and health services/practice (various levels and contexts – clinical treatment, information, IT systems, pharmacy, laboratories, nutrition)
     
  • Research covering all relevant disciplines and diverse dimensions of ARV treatment and related themes
  • Training and evaluation of training
  • Patients, communities and civil society organisations
  • Public, private, NGO, FBO initiatives and partnerships

Emphasis will be on the Free State, however, with of significant involvement from other provinces, SADC countries, and countries further a field. The thrust will be to export lessons and experiences from the Free State, but also to import lessons and experiences from other provinces, countries and sectors.

Presenters
Key presenters from the Free State, other provinces, South Africa, from the private, FBO and NGO sectors, and from several other countries

Delegates
About half of the delegates will be Free State stakeholders and role players (all levels and all contexts). The other half will be role players and stakeholders in the ARV and related fields from other provinces, the national level, and other countries, as well as from the private, public and non-governmental sectors.

Focused workshops
Provision will be made for half-a-day or one-day workshop initiatives on the third day (1 April 2005).

Enquiries
For more information please contact:

Prof Dingie van Rensburg
Centre for Health Systems Research & Development
University of the Free State
PO Box 339
Bloenfontein
SOUTH AFRICA
9300

Contact:
Carin van Vuuren
Conference Organiser
Centre for Health Systems Research & Development
University of the Free State
P.O.Box 339
Bloemfontein
South Africa
9300
Tel +27 (0) 51 401 2181
Fax +27 (0) 51 4480370
Cell 0832932890
e-mail: arvconference.hum@mail.uovs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept